Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Liverpool | OTHER |
| Oslo University Hospital | OTHER |
| Cures Within Reach | OTHER |
| Open Philanthropy |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to determine a universal safe and effective dose of sodium bicarbonate for use among women with Obstructed labour to treat acidosis. It will also learn about the safety of sodium bicarbonate drug among women with Obstructed labour.
Researchers will compare sodium bicarbonate drug to normal saline (a look-alike solution) to see if sodium bicarbonate works to treat acidosis.
Participants will receive sodium bicarbonate solution or a placebo up to two doses, four hours apart.
Oral bicarbonate is a safe, cheap and effective acid buffer, widely used in sports to improve performance because of its ability to prevent and reverse the effects of metabolic acidosis. Clinically, it is used in intensive care units to treat patients with overwhelming infections or poisoning. In low resource settings, obstructed labor (OL) is a major problem that accounts for 22% of maternal deaths. The fetal harm of OL comes from intrapartum asphyxia, characterized by accumulation of hydrogen ions that cross the placental barrier to cause fetal acidosis. Acidosis causes failure of basic cellular functions resulting into cell death. In a recent Randomised Clinical Trial, the investigators found that 61% of 477 women with OL were acidotic (lactate >4.8 mmol/L), with a median capillary blood lactate level of 6.9 (3.4-13) mmol/L.
The investigators propose an early phase III, placebo-controlled dose-ranging trial to determine the efficacy and safety of a pre-operative infusion of sodium bicarbonate in women with obstructed labour (OL). In a ratio of 1:1:1: 1 100 mls (8.4g), 150 mls (12.6g) and 200 mls (16.8g) of 8.4% sodium bicarbonate solution, or placebo (50 mls of Normal Saline 0.9%). The primary outcome will be mean change in acidosis (pH and lactate levels) from baseline. The secondary outcomes will be neonatal death, safety of sodium bicarbonate, pharmacokinetics of sodium bicarbonate in pregnant women, primary postpartum haemorrhage, sepsis, and maternal death.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 8.4g of 8.4% sodium bicarbonate solution Arm | Experimental | Each participant will receive 100mls of 8.4g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart. |
|
| 12.6g of 8.4% sodium bicarbonate solution Arm | Experimental | Each participant will receive 150mls of 12.6g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart. |
|
| 16.8g of 8.4% sodium bicarbonate solution Arm | Experimental | Each participant will receive 200mls of 16.8g, 8.4% sodium bicarbonate solution, up to two doses, four hours apart. |
|
| Normal Saline 0.9% Arm | Active Comparator | Each participant will receive 50mls of Normal Saline 0.9%, up to two doses, four hours apart. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 8.4% sodium bicarbonate solution | Drug | Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean change in maternal pH from baseline in each group | At baseline, 30, 60, 90, 120 and 150 minutes | |
| Mean umbilical blood pH in each arm of the study | At baseline, 30, 60, 90, 120 and 150 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Mean lactate in maternal and umbilical blood, | At baseline and at birth. | |
| Number of early neonatal deaths | Within 7 days | |
| Safety of sodium bicarbonate (comparison of the proportion of participants that get side effects in each arm) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Trond Michelsen, PhD | Oslo University Hospital | Principal Investigator |
| David Mukunya, PhD | Busitema University | Principal Investigator |
| Julius Wandabwa, PhD | Busitema University | Principal Investigator |
| Kenneth Mugabe, MD | Busitema University | Principal Investigator |
| Dan Kibuule, PhD | Busitema University | Principal Investigator |
| Andrew Weeks, MD | University of Liverpool | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mbale Regional Referral Hospital | Mbale | Uganda |
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be freely available.
Immediately following publication, No end date
Anyone who wishes to access the data. Any types of data analyses will be permitted.
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 10, 2025 | Apr 14, 2026 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D004420 | Dystocia |
| ID | Term |
|---|---|
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| 0.9% Normal Saline | Other | The comparision group will receive 50 mls of 0.9% Normal Saline |
|
| Within 24 hours after administration of the drug |
| Number of mothers that get primary postpartum hemorrhage | Within 24 after birth |